Detailed information for compound 1723052
Basic information
Technical information
- Name: Unnamed compound
- MW: 358.364 | Formula: C19H19FN2O4
-
H donors: 2
H acceptors: 3
LogP: 2.57
Rotable bonds: 5
Rule of 5 violations (Lipinski): 1 - SMILES: CCc1ccc(c(c1)O)Oc1ccc(cc1F)C(=O)N1CCNC(=O)C1
- InChi: 1S/C19H19FN2O4/c1-2-12-3-5-17(15(23)9-12)26-16-6-4-13(10-14(16)20)19(25)22-8-7-21-18(24)11-22/h3-6,9-10,23H,2,7-8,11H2,1H3,(H,21,24)
- InChiKey: WUOZMZMHRFAYPT-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Staphylococcus aureus | Enoyl-[acyl-carrier-protein] reductase [NADPH] | Starlite/ChEMBL | References |
| Staphylococcus aureus (strain NCTC 8325) | Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | Starlite/ChEMBL | No references |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0447 | 0.2605 | 0.5 |
| Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0447 | 0.2605 | 0.5 |
| Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0447 | 0.2605 | 0.5 |
| Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0831 | 0.8878 | 1 |
| Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0447 | 0.2605 | 0.5 |
| Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0731 | 0.7241 | 1 |
| Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0662 | 0.6119 | 0.8166 |
| Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0447 | 0.2605 | 0.5 |
| Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0447 | 0.2605 | 0.5 |
| Trichomonas vaginalis | hypothetical protein | 0.0447 | 0.2605 | 0.5 |
| Loa Loa (eye worm) | glutamate receptor | 0.0731 | 0.7241 | 0.7241 |
| Schistosoma mansoni | metabotropic glutamate receptor | 0.0612 | 0.5304 | 0.5392 |
| Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0447 | 0.2605 | 0.5 |
| Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0447 | 0.2605 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| ED50 (ADMET) | > 32 ug ml-1 | Cytotoxicity against human HepG2 cells | ChEMBL. | 23092194 |
| IC50 (binding) | = 29 nM | BindingDB_Patents: Inhibition Assay. The assay buffer AB contained 50 mM ADA (N-(2-acetamido)iminodiacetic acid monosodium salt) pH 6.5, 1 mM dithiothreitol, 0.006% Triton-X100 and 50 mM NaCl. The following components are added in a white polystyrene Costar plate (Ref 3912) up to a final volume of 55.5 uL: 1.5 uL DMSO or inhibitor dissolved in DMSO and 54 uL of a FabI/NADPH/NADP+ mixture in AB. After 60 min of pre-incubation at room temperature, the reaction is started by addition of 5 uL of trans-2-octenoyl N-acetylcysteamine thioester (t-o-NAC) to a final volume of 60.5 uL. This reaction mixture is then composed of 2 nM FabI, 40 uM NADPH (Sigma, N7505), 10 uM NADP+ (Sigma, N5755), 100 uM t-O-NAC and compound at defined concentration. Fluorescence intensity of NADPH (lamda=ex=360 nm, lamda=em=520 nm) is measured immediately after t-O-NAC addition (T0), and approximately 50 min later (T50) by a Fluostar Optima (BMG). | ChEMBL. | No reference |
| IC50 (binding) | = 29 nM | BindingDB_Patents: Inhibition Assay. The assay buffer AB contained 50 mM ADA (N-(2-acetamido)iminodiacetic acid monosodium salt) pH 6.5, 1 mM dithiothreitol, 0.006% Triton-X100 and 50 mM NaCl. The following components are added in a white polystyrene Costar plate (Ref 3912) up to a final volume of 55.5 uL: 1.5 uL DMSO or inhibitor dissolved in DMSO and 54 uL of a FabI/NADPH/NADP+ mixture in AB. After 60 min of pre-incubation at room temperature, the reaction is started by addition of 5 uL of trans-2-octenoyl N-acetylcysteamine thioester (t-o-NAC) to a final volume of 60.5 uL. This reaction mixture is then composed of 2 nM FabI, 40 uM NADPH (Sigma, N7505), 10 uM NADP+ (Sigma, N5755), 100 uM t-O-NAC and compound at defined concentration. Fluorescence intensity of NADPH (lamda=ex=360 nm, lamda=em=520 nm) is measured immediately after t-O-NAC addition (T0), and approximately 50 min later (T50) by a Fluostar Optima (BMG). | ChEMBL. | No reference |
| IC50 (binding) | = 0.028 uM | Inhibition of Staphylococcus aureus recombinant FabI using trans-2-octenoyl N-acetylcysteamine thioester as substrate preincubated for 60 mins | ChEMBL. | 23092194 |
| MIC (functional) | = 8 ug ml-1 | Antibacterial activity against Escherichia coli C7 after 18 hrs by broth microdilution method | ChEMBL. | 23092194 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL2178286
Bibliographic References
No literature references available for this target.
If you have references for this compound, please enter them in a user comment (below) or Contact us.